TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31392337
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg Cr/kg diet (10× the approved level)
Study: 26615448
Drug: Inhaled epinephrine
Normalized name: epinephrine Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled epinephrine (4 mg/mL solution administered during mean 18 min)
Study: 26615448
Drug: Intramuscular epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular epinephrine (0.3 mg)
Study: 24344941
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine as add-on therapy (n=17)
Study: 18425538
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL 0.25% levobupivacaine and 40 mg methylprednisolone before wound closure
Study: 18425538
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL 0.25% levobupivacaine alone before closure
Study: 18425538
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL 0.25% levobupivacaine and 40 mg methylprednisolone before incision
Study: 18425538
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL 0.25% levobupivacaine alone before incision
Study: 18425538
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL 0.9% NaCl before wound closure
Study: 12491025
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg) + THC (30 mg)
Study: 12491025
Drug: THC (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (0, 15, 30 mg) with active naltrexone (50 mg)
Study: 12491025
Drug: THC (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (0, 15, 30 mg) with placebo naltrexone
Study: 12491025
Drug: Methadone (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (5, 10 mg)
Study: 11140433
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) - oral (5 to 40 mg), inhaled (500 to 2000 microg), intravenous (250 to 1000 g)
Study: 8865055
Drug: Moderate-dose lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate-dose lidocaine (3 mg/kg)
Study: 8865055
Drug: Low-dose lidocaine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose lidocaine (1.5 mg/kg)
Study: 1531469
Drug: Intratubal injection
Normalized name: ALCOHOL 80 mL in 100 mL INTRADURAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratubal injection of methotrexate (MTX)
Study: 31078124
Drug: Dental pattern
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dental pattern analysis system with treatment chronology on panoramic radiography
Study: 27739188
Drug: Bupropion (BUP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (BUP; 4 × 150 mg)
Study: 23557110
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion (10% glucose, 2.5 mL/kg/h)
Study: 23557110
Drug: Glucose-insulin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin infusion (10% glucose added 30 IU NovoRapid® per litre, 2.5 mL/kg/h)
Study: 19070855
Drug: Medication management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication management training for CMHPs
Study: 14993509
Drug: Intraperitoneal tinzaparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal tinzaparin (low‐molecular weight heparin) administered once a day for 3 months
Study: 9650015
Drug: Cream meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream meal
Study: 8587293
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g MMF daily
Study: 8587293
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g MMF daily
Study: 2568816
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period (baseline measurements before CM injection)
Study: 579125
Drug: Etofenamate (Rheumon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etofenamate (Rheumon Gel)
Study: 28187952
Drug: AS03-adjuvanted H7N1
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted H7N1 vaccine (3.75 or 7.5μg hemagglutinin with AS03A or AS03B)
Study: 28187952
Drug: Unadjuvanted H7N1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unadjuvanted H7N1 vaccine (15μg hemagglutinin)
Study: 23324131
Drug: pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pemetrexed 500 mg/m² + cisplatin 75 mg/m² IV every 21 days × 3 cycles, followed by surgery and hemithoracic radiation (54 Gy)
Study: 15148493
Drug: Both G‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both G‐CSF and GM‐CSF
Study: 9830189
Drug: Antihistamines as
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamines as substitute hypnotics
Study: 29357033
Drug: Resveratrol 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 800 mg/day for 2 months
Study: 16029678
Drug: 10% green
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% green tea cream and 300 mg twice‐daily green tea oral supplementation
Study: 598301
Drug: 0.24 g
Normalized name: Sodium Fluoride 0.24 g in 100 g DENTAL PASTE [AM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.24 g i.v. Theophylline-ethylenediamine
Study: 598301
Drug: 0.72 g
Normalized name: SALICYLIC ACID 0.72 g in 0.72 g TOPICAL GEL [SA Oil Free Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.72 g infusion over four hours
Study: 598301
Drug: 0.36 g
Normalized name: ARBUTIN 0.36 g in 5 g CUTANEOUS LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.36 g i.m. injection
Study: 598301
Drug: 0.72 g
Normalized name: SALICYLIC ACID 0.72 g in 0.72 g TOPICAL GEL [SA Oil Free Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.72 g infusion over 6-8 hours
Study: 30230204
Drug: Long-term administration
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term administration of human albumin (20 g twice per week)
Study: 27161901
Drug: Weight changes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight changes across treatment arms
Study: 21617110
Drug: Bedtime treatment
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime treatment with ≥1 hypertension medications
Study: 21617110
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (all medications ingested in the morning)
Study: 16501287
Drug: Thrombectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombectomy with Mt-PA pre-administration (group T)
Study: 7690046
Drug: Intelligent dosing
Normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intelligent dosing system (IDS) for FK506
Study: 2876122
Drug: Prolonged continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged continuous treatment with propranolol and other anti-arrhythmic drugs
Study: 30158072
Drug: Non-LLA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-LLA group (no lipid-lowering treatment) with amlodipine
Study: 30158072
Drug: Non-LLA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-LLA group (no lipid-lowering treatment) with atenolol
Study: 28659038
Drug: Joint treatment
Normalized name: ARNICA MONTANA FLOWER 2 g in 20 g / APIS MELLIFERA VENOM 6 g in 20 g TOPICAL CREAM [HOUKEA Venom Flex Joint Treatment Balm]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint treatment (fluoxetine + CBT)
Study: 28659038
Drug: Single active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single active treatment (fluoxetine or CBT)
Study: 20199136
Drug: Mealtime pramlintide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mealtime pramlintide (PRAM) 120 microg fixed dose
Study: 20199136
Drug: Titrated rapid-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated rapid-acting insulin analogs (RAIAs)
Study: 12739832
Drug: GM-CSF (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF (not specified dose)
Study: 11789263
Drug: Conventional medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medicine (CM)
Study: 9383258
Drug: Loratadine 10
Normalized name: loratadine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine 10 mg/day
Study: 8222794
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg twice daily for 7 to 14 days)
Study: 8222794
Drug: Cefixime (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (400 mg once daily for 7 to 14 days)
Study: 26726885
Drug: Ibuprofen (400mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400mg every 8 hrs)
Study: 18983789
Drug: Bupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine with midazolam (30 ml of 0.5% bupivacaine with midazolam 50 microg x kg‐1)
Study: 18983789
Drug: Bupivacaine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (30 ml of 0.5% bupivacaine)
Study: 11074901
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention (patient education, training for participation, self-monitoring of prothrombin time, guideline-based management of warfarin dosing)
Study: 8315546
Drug: Meperidine 2
Normalized name: meperidine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 2 mg/kg (M)
Study: 8315546
Drug: Low-dose meperidine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose meperidine 1 mg/kg and diazepam 0.1 mg/kg (M low+D)
Study: 8315546
Drug: High-dose meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose meperidine 2 mg/kg and diazepam 0.1 mg/kg (M high+D)
Study: 8315546
Drug: Diazepam 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.1 mg/kg (D)
Study: 27247843
Drug: Medication (active-comparator)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (active-comparator)
Study: 27247843
Drug: Medication (medication)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (medication)
Study: 12566494
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet supplemented with 2 mg Cu/d for 6 weeks
Study: 12566494
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet supplemented with 1.0 mg Cu/d during equilibration
Study: 10385496
Drug: Single-dose ascorbic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose ascorbic acid (2 g PO)
Study: 10385496
Drug: Long-term ascorbic
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term ascorbic acid (500 mg/d)
Study: 31119466
Drug: IP6 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: IP6 (600 mg twice daily)
Study: 23348636
Drug: Mericitabine 500
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Mericitabine 500 mg BID for 12 weeks + Peg-IFNα-2a/RBV
Study: 23348636
Drug: Mericitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mericitabine 1000 mg BID for 8 weeks + Peg-IFNα-2a/RBV
Study: 23348636
Drug: Mericitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mericitabine 1000 mg BID for 12 weeks + Peg-IFNα-2a/RBV
Study: 19297102
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg 17‐beta estradiol daily and 0.35 mg norethindrone 3 days/week
Study: 17989859
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement (50 g daily for 3 months)
Study: 15381516
Drug: Manipulative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulative therapy (up to 6 treatment sessions in a 12-week period)
Study: 11378603
Drug: Pentoxifylline (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (loading bolus of 300 mg followed by a continuous infusion of 1.5 mg.kg‐1.hr‐1 until the second postoperative day)
Study: 8078656
Drug: Other three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other three lidocaine solutions (not specified)
Study: 2676654
Drug: 1500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg/day clofibrate
Study: 25973909
Drug: ABT-089 (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-089 (5, 10, 15, 20, 30, or 35 mg once daily)
Study: 10960046
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of GTN (0.5 microg/kg per minute for 20 min)
Study: 10960046
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of GTN
Study: 3876031
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g every four hours)
Study: 3876031
Drug: Cimetidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (2 g intravenously)
Study: 3876031
Drug: Antacids (every
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids (every two hours)
Study: 3876031
Drug: Pirenzepine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (50 mg intravenously daily)
Study: 29091470
Drug: Caffeinated chewing
Normalized name: caffeine Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated chewing gum (200 mg caffeine)
Study: 29091470
Drug: Caffeinated chewing
Normalized name: caffeine Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated chewing gum (200 mg caffeine) in low habitual caffeine consumers (<40 mg/day)
Study: 29091470
Drug: Placebo (noncaffeinated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (noncaffeinated chewing gum) in low habitual caffeine consumers (<40 mg/day)
Study: 29091470
Drug: Caffeinated chewing
Normalized name: caffeine Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated chewing gum (200 mg caffeine) in moderate/high habitual caffeine consumers (>130 mg/day)
Study: 29091470
Drug: Placebo (noncaffeinated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (noncaffeinated chewing gum) in moderate/high habitual caffeine consumers (>130 mg/day)
Study: 27046296
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (mirror therapy and comparison)
Study: 19096961
Drug: 30-60 min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-60 min of oral and written information on lifestyle intervention
Study: 10758049
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MRCA and x-ray coronary angiography
Study: 23519576
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 600 mg
Study: 16430561
Drug: Levobupivacaine 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 12 mg
Study: 16430561
Drug: Ropivacaine 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 17 mg
Study: 11773294
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus TAM
Study: 9564793
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (TAA) 400 microg twice daily
Study: 7752836
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of Coenzyme Q10 (CoQ10) once a week for 6 weeks
Study: 3357071
Drug: VT‐1 (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: VT‐1 (no uncertainty, prescribed therapy)
Study: 3357071
Drug: VT‐2 (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: VT‐2 (no uncertainty, prescribed therapy)
Study: 3357071
Drug: VT‐3 (expressed
Approvals — FDA: no, EMA: no, PMDA: no
Description: VT‐3 (expressed uncertainty, prescribed antibiotics without resolution)
Study: 31332977
Drug: Daily vacuuming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vacuuming of mattresses for 2 weeks
Study: 23743404
Drug: Local BH4
Normalized name: 6R-BH4
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Local BH4 administration
Study: 16364159
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) 200 microg twice daily (400 microg/day)
Study: 15243285
Drug: Transdermal 17beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17beta‐estradiol (50 microg/day) and nomegestrol (5 mg/day for 12 days/month)
Study: 15243285
Drug: Transdermal 17beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17beta‐estradiol and nomegestrol (HT)
Study: 10654500
Drug: Propranolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (20 mg four times daily)
Study: 10654500
Drug: Propranolol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol + Magnesium (18 g over 24 hours)
Study: 8356371
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ketoprofen controlled release (morning dose)
Study: 8356371
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ketoprofen controlled release (evening dose)
Study: 8356371
Drug: Both morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both morning and evening doses of ketoprofen
Study: 28833181
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment procedures (radiofrequency ablation, microdebrider-assisted inferior turbinoplasty)
Study: 22543555
Drug: Neurocognitive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurocognitive and perceptive rehabilitation treatment (TG)
Study: 22543555
Drug: Common physical
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common physical therapy (CG)
Study: 20861328
Drug: Mtb72F/AS02(A) (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mtb72F/AS02(A) (10 μg antigen)
Study: 20861328
Drug: Mtb72F/AS02(A) (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mtb72F/AS02(A) (40 μg antigen)
Study: 20861328
Drug: Mtb72F/AS02(A) (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mtb72F/AS02(A) (10 or 40 μg antigen)
Study: 18384663
Drug: 20‐mg rabeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20‐mg rabeprazole once daily for 4 weeks
Study: 18384663
Drug: 20‐mg rabeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20‐mg rabeprazole once daily for 8 weeks
Study: 8363291
Drug: 12.5mg of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5mg of timolol (2.5mL of timolol 0.5% ophthalmic solution)
Study: 8363291
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of caffeine and timolol
Study: 30982378
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg twice daily plus MTX
Study: 30982378
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg every 2 weeks plus MTX
Study: 28280092
Drug: Enzalutamide monotherapy
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide monotherapy (n = 29)
Study: 28280092
Drug: Enzalutamide in
Normalized name: Product containing enzalutamide in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzalutamide in combination with endocrine therapies (n = 70)
Study: 28280092
Drug: Exemestane 50
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane 50 mg/day given with enzalutamide
Study: 11346805
Drug: Transesophageal echocardiography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transesophageal echocardiography guided treatment
Study: 9288409
Drug: Secobarbital sodium
Normalized name: Secobarbital Sodium
DrugBank: Secobarbital (DB00418)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Secobarbital sodium (2.9 mg/kg body weight)
Study: 8506770
Drug: Antimicrobial prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial prophylaxis (ceftriazone, 1 gr intramuscular)
Study: 21765198
Drug: Stepwise protocol
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stepwise protocol for the treatment of pain (paracetamol, morphine, buprenorphine transdermal patch, pregabaline) for eight weeks
Study: 21765198
Drug: Stepwise protocol
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stepwise protocol for the treatment of pain
Study: 12750665
Drug: 2-phase treatment
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-phase treatment with headgear/biteplate
Study: 8795760
Drug: Topical verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical verapamil 0.063%, 0.125%, and 0.25%
Study: 8795760
Drug: Topical verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical verapamil 0.25%
Study: 6152055
Drug: IV alprazolam
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV alprazolam (1.0 mg)
Study: 6152055
Drug: Oral alprazolam
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alprazolam (1.0 mg)
Study: 6152055
Drug: IV and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV and oral alprazolam (1.0 mg)
Study: 31553712
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline injection (experimental neck pain)
Study: 26724641
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg/d) plus gefitinib (250 mg/d)